BioMarin ( BioMarin )

BioMarin

BioMarin's picture

The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS).

BioMarin press release, blog etc

10/18/2017 - 15:41 BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
10/18/2017 - 08:41 Popular Science Names BioMarin's Brineura (cerliponase alfa) One of the Top Health Innovations of 2017 with "Best of What's New" Award
10/11/2017 - 09:05 BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York
10/03/2017 - 06:44 BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
09/14/2017 - 13:06 FDA Not Currently Planning to Hold Advisory Committee Meeting for BioMarin's Pegvaliase Biologics License Application (BLA)
09/06/2017 - 09:31 BioMarin Presents Interim Data of Phase 1/2 Study of BMN 250 for Treatment of Sanfilippo B Syndrome (MPS IIIB) at 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017
09/05/2017 - 11:17 BioMarin Announces 3 Platform and 15 Poster Presentations at 13th International Congress of Inborn Errors of Metabolism 2017
08/29/2017 - 17:21 FDA Accepts BioMarin's Pegvaliase Biologics License Application (BLA) and Grants Priority Review Designation
08/23/2017 - 12:19 BioMarin Announces Exercise in Full of Underwriters' Option to Purchase Additional 0.599% Senior Subordinated Convertible Notes Due 2024
08/21/2017 - 12:08 Forbes Ranks BioMarin 12th Most Innovative Company in the World
08/07/2017 - 16:26 BioMarin Announces Offering of $450 Million of Senior Subordinated Convertible Notes Due 2024
08/06/2017 - 21:03 BioMarin Announces Offering of $450 Million of 0.599% Senior Subordinated Convertible Notes Due 2024
08/02/2017 - 13:11 BioMarin Announces Plans to Progress Both the 6e13vg/kg and 4e13 vg/kg Doses of BMN 270, its Investigational Gene Therapy for Hemophilia A, into Phase 3 Studies
06/29/2017 - 20:57 BioMarin Submits Pegvaliase Biologics License Application (BLA) to the U.S. FDA for Treatment of Phenylketonuria (PKU)
06/15/2017 - 21:51 BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress
06/01/2017 - 07:48 European Commission Approves Brineura (cerliponase alfa), the First Treatment for CLN2 Disease, a Form of Batten Disease and Ultra-Rare Brain Disorder in Children
05/02/2017 - 07:38 BioMarin to Attend Two Upcoming Investor Conferences
04/27/2017 - 08:41 FDA Approves Brineura (cerliponase alfa) for the Treatment of CLN2 Disease, a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children